The latest articles, press releases and dossiers on diagnostics in Baden-Württemberg
Article - 14-Apr-2016
In cooperation with industrial partners, researchers at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have spent many years developing innovative diagnostic tools for use in infection biology. Among these are microsystems that combine complete test procedures on a “lab-on-a-chip” (LOC) and enable simultaneous analysis of several thousand parameters relatively quickly and with little effort. The scientists hope that these systems will soon be ready for application in routine diagnostics.
Article - 24-Mar-2016
The Meet & Match event “Optical Imaging: Future Trends in Medical Applications” – organised by BIOPRO Baden-Württemberg GmbH and the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB) in Mannheim on 9th March 2016 - attracted around 80 participants. Interesting lectures provided in-depth insights into future trends in optical imaging in medical applications.
Article - 14-Mar-2016
Being able to diagnose and treat tumour patients in just a few hours is just one of the many promising goals of the Fraunhofer Project Group for Automation in Medicine and Biotechnology (PAMB). The overall goal of the Intervention and Therapy research group is to take innovative technologies for diagnostic and therapeutic interventions from laboratory development to prototype production for use in clinical trials.
Article - 03-Mar-2016
Researchers around the world, including researchers from the Freiburg University Medical Center, are working on developing simple blood tests, so-called liquid biopsies, that can be used to obtain accurate information about tumour staging and the progress of therapy. An international liquid biopsy symposium was held in Freiburg in October 2015 and has produced valuable insights.
Article - 02-Feb-2016
EIT Health is a large-scale European project launched in December 2014 that aims to help people in Europe to live a healthier life and stay active as they grow older. The consortium brings together 140 leading companies and institutions from 14 European countries and has a total budget of two billion euros. It is one of the largest networks worldwide in the healthcare sector.
Article - 21-Jan-2016
DNA sequencing has become indispensable in modern science. Innovative advances that will bring about changes in the life sciences and medicine are due to rapid developments in genome analysis technologies. In the interview below, Peter Pohl, CEO and co-founder of GATC Biotech AG, explains why DNA sequencing will become even more important in future.
Article - 11-Jan-2016
People with obesity suffer from more than just health problems related to their weight. They often feel socially stigmatised because their disease is often seen as a self-inflicted condition. A new study by the University of Hohenheim in cooperation with the eSwiss Medical and Surgical Center in St. Gallen now shows that severe obesity is closely associated with gene activity in the intestinal tissue. This activity is responsible for producing hormones that control the energy metabolism.
Article - 17-Nov-2015
In the ”NanoBioMater”project house, researchers from the University of Stuttgart are working to develop novel hydrogels with integrated biocompatible scaffold structures. Their aim is to make the materials suitable for producing innovative components for environmental and food analytics as well as medical applications. The hydrogels could potentially be used in diagnostic biosensors and the controlled release of medical compounds.
Article - 28-Sep-2015
It would be phenomenal news if it turned out that breast cancer could be detected by way of urine samples. Treating physicians would be able to use conspicuous test results to begin further examinations as quickly as possible along with therapy if necessary. Prof. Dr. Elmar Stickeler and his team from the Freiburg University Medical Centre have developed a method that identifies the composition of microRNAs in urine. They were able to predict with over 91 percent accuracy whether a tumour was present or not. They have now filed a patent for the method.
Article - 24-Sep-2015
The number of people suffering from oral or oropharyngeal cancer is rising steadily. The major cause of these cancers is human papillomaviruses (HPV) that colonise the oral cavity, where they are difficult to detect. QIAGEN Lake Constance GmbH from Stockach, in cooperation with Abviris Deutschland GmbH, has developed a new test system to improve the detection of oral HPV. This new system enables rapid and reliable quantitative detection of HPV-specific antibodies outside of a central laboratory and is intended to make it possible in the future to initiate cancer treatment at an early stage.
Article - 21-Sep-2015
Nanoparticles are already used in many materials and areas, ranging from textiles to scientific and medical research. The global scientific community is keenly interested in nanoparticle research and Prof. Dr. Hans-Peter Deigner, professor in the Faculty of Medical and Life Sciences at Furtwangen University of Applied Sciences (HFU) is no exception. Deigner works on optimising nanoparticles for application in lateral flow assays. As well as carrying out intensive research into biomarkers, Deigner is also dean of the HFU’s Faculty of Medical and Life Sciences and president of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB).
Press release - 18-Sep-2015
Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the development of the operating production and sales activities as well as the further advancements of Biametrics’ label- free analytical devices for the life science market.